Addex Therapeutics Ltd (ADXN) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ADXN Revenue Growth
Revenue Breakdown (FY 2024)
ADXN's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
ADXN Revenue Analysis (2013–2024)
As of May 8, 2026, Addex Therapeutics Ltd (ADXN) generated trailing twelve-month (TTM) revenue of $67,607, reflecting significant decline in growth of -44.8% year-over-year. The most recent quarter (Q3 2025) recorded $29,724 in revenue, down 18.3% sequentially.
Looking at the longer-term picture, ADXN's 5-year compound annual growth rate (CAGR) stands at -31.9%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $6.0 million in 2018.
Revenue diversification analysis shows ADXN's business is primarily driven by Research (100%). With over half of revenue concentrated in Research, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ACAD (+9.9% YoY), INVA (+13.6% YoY), and NBIX (+28.6% YoY), ADXN has underperformed the peer group in terms of revenue growth. Compare ADXN vs ACAD →
ADXN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ADXNCurrent | $67,607 | -44.8% | -31.9% | -681.8% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 NBIX | $2.9B | +28.6% | +22.3% | 21.6% |
ADXN Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $404K | -74.9% | $404K | 100.0% | $-2,755,233 | -681.8% |
| 2023 | $1.6M | +13.4% | $1.6M | 100.0% | $-2,242,967 | -139.1% |
| 2022 | $1.4M | -51.2% | $1.4M | 100.0% | $-10,540,901 | -741.0% |
| 2021 | $2.9M | -19.3% | $2.9M | 100.0% | $-15,505,917 | -531.7% |
| 2020 | $3.6M | +30.8% | $3.6M | 100.0% | $-12,243,274 | -338.9% |
| 2019 | $2.8M | -54.3% | $2.5M | 91.7% | $-14,604,157 | -528.6% |
| 2018 | $6.0M | +1109.0% | $5.9M | 97.6% | $-1,424,625 | -23.6% |
| 2017 | $500K | +2784.7% | $470K | 94.0% | $-3,235,056 | -647.1% |
| 2016 | $17K | -57.0% | $0 | - | $-3,129,597 | -18059.9% |
| 2015 | $40K | -52.8% | $0 | - | $-3,867,945 | -9597.6% |
See ADXN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ADXN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ADXN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonADXN — Frequently Asked Questions
Quick answers to the most common questions about buying ADXN stock.
Is ADXN's revenue growth accelerating or slowing?
ADXN revenue declined -44.8% year-over-year, contrasting with the 5-year CAGR of -31.9%. TTM revenue fell to $67607.00. This reverses the prior growth trend.
What is ADXN's long-term revenue growth rate?
Addex Therapeutics Ltd's 5-year revenue CAGR of -31.9% reflects the variable expansion pattern. Current YoY growth of -44.8% is below this long-term average.
How is ADXN's revenue distributed by segment?
ADXN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.